FY2024 EPS Forecast for LeMaitre Vascular Lifted by Analyst

LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) - Analysts at Barrington Research lifted their FY2024 earnings per share (EPS) estimates for LeMaitre Vascular in a research note issued to investors on Friday, November 1st. Barrington Research analyst M. Petusky now expects that the medical instruments supplier will earn $1.94 per share for the year, up from their prior forecast of $1.87. Barrington Research has a "Outperform" rating and a $93.00 price objective on the stock. The consensus estimate for LeMaitre Vascular's current full-year earnings is $1.86 per share. Barrington Research also issued estimates for LeMaitre Vascular's Q4 2024 earnings at $0.49 EPS, Q1 2025 earnings at $0.54 EPS, Q3 2025 earnings at $0.55 EPS and FY2025 earnings at $2.28 EPS.

Several other analysts have also recently issued reports on LMAT. JMP Securities increased their target price on LeMaitre Vascular from $77.00 to $100.00 and gave the stock a "market outperform" rating in a research report on Tuesday, August 20th. Oppenheimer reissued an "outperform" rating and set a $93.00 price target (up from $90.00) on shares of LeMaitre Vascular in a research note on Friday. Lake Street Capital assumed coverage on LeMaitre Vascular in a report on Friday, August 2nd. They set a "buy" rating and a $105.00 price target for the company. StockNews.com cut LeMaitre Vascular from a "buy" rating to a "hold" rating in a report on Tuesday, August 27th. Finally, Cantor Fitzgerald assumed coverage on LeMaitre Vascular in a report on Tuesday, October 15th. They set a "neutral" rating and a $96.00 price target for the company. Three analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, LeMaitre Vascular presently has an average rating of "Moderate Buy" and a consensus target price of $94.57.

LeMaitre Vascular Price Performance

Shares of NASDAQ:LMAT traded up $1.47 during trading on Monday, hitting $96.35. 207,634 shares of the company's stock were exchanged, compared to its average volume of 123,743. LeMaitre Vascular has a 52-week low of $47.72 and a 52-week high of $101.67. The business's 50-day simple moving average is $89.59 and its 200 day simple moving average is $83.25. The company has a market cap of $2.16 billion, a price-to-earnings ratio of 51.85, a PEG ratio of 2.32 and a beta of 0.89.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last released its earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.05. LeMaitre Vascular had a return on equity of 13.39% and a net margin of 19.40%. The firm had revenue of $54.82 million during the quarter, compared to analysts' expectations of $53.50 million. During the same quarter last year, the business posted $0.33 earnings per share. The firm's revenue was up 15.6% on a year-over-year basis.

LeMaitre Vascular Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 5th. Stockholders of record on Thursday, November 21st will be issued a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.66%. The ex-dividend date is Thursday, November 21st. LeMaitre Vascular's dividend payout ratio (DPR) is 34.97%.

Insider Transactions at LeMaitre Vascular

In other news, Director David B. Roberts sold 3,063 shares of LeMaitre Vascular stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $82.07, for a total value of $251,380.41. Following the completion of the transaction, the director now owns 14,114 shares in the company, valued at approximately $1,158,335.98. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 10.79% of the company's stock.

Hedge Funds Weigh In On LeMaitre Vascular

A number of large investors have recently bought and sold shares of the business. Los Angeles Capital Management LLC boosted its holdings in LeMaitre Vascular by 23.1% during the 3rd quarter. Los Angeles Capital Management LLC now owns 33,656 shares of the medical instruments supplier's stock valued at $3,126,000 after acquiring an additional 6,320 shares during the period. Atria Investments Inc raised its position in LeMaitre Vascular by 43.9% during the 3rd quarter. Atria Investments Inc now owns 8,853 shares of the medical instruments supplier's stock valued at $822,000 after purchasing an additional 2,701 shares in the last quarter. Summit Global Investments raised its position in LeMaitre Vascular by 2.4% during the 3rd quarter. Summit Global Investments now owns 6,192 shares of the medical instruments supplier's stock valued at $575,000 after purchasing an additional 146 shares in the last quarter. Portside Wealth Group LLC bought a new stake in LeMaitre Vascular during the 3rd quarter valued at $497,000. Finally, Robeco Institutional Asset Management B.V. bought a new stake in LeMaitre Vascular during the 3rd quarter valued at $283,000. Hedge funds and other institutional investors own 84.64% of the company's stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.